Objectives
The Antibodies and Peptides Unit focuses on the in-silico design and production of antibodies and peptides at laboratory scale.
Areas of impact and applications in the field
The Antibodies and Peptides Unit is essential for designing and producing antibodies and peptides at the lab scale. Targeted therapies based on antibodies are becoming increasingly important in cancer treatment. Antibody theranostics, which combines the diagnostic and therapeutic potential of an antibody, is another prospective research area for this facility.
Areas of impact and applications in the field
Regarding cancer research, synthetic biology seeks to re-design biological systems to perform novel functions in a predictable way. Recent advances in bacterial and mammalian cell engineering include the development of cells that function in biological samples or within the body as minimally invasive diagnostics or theranostics for the real-time regulation of complex pathological conditions. Ex-vivo and in-vivo cell-based biosensors and therapeutics have been developed to target a wide range of diseases including cancer.
A major milestone in the field of theranostic cell engineering was the 2017 FDA approval of tisagenlecleucel, the first gene therapy to be approved in the USA. Considering the above, this facility will work on preclinical applications of mammalian sensing and drug delivery platforms as well as underlying biological designs that could lead to new classes of cell diagnostics and therapeutics.
In the context of infectious diseases, there is a growing need for novel, specific, sensitive, and effective diagnostic and treatment procedures. Synthetic systems and devices are evolving into strong tools for treating human infections. The advancement of synthetic biology provides platforms for detecting and preventing infectious diseases that are efficient, accurate, and cost-effective.
Services
List of Equipments
